An interventional study of Far red light therapy and Sham light therapy in Peripheral Artery Disease, Peripheral Vascular Disease and Aging, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Northwestern University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Peripheral Arterial Disease by Northwestern University — 8 open to participants now, 10 under way, 4 of them phase 3. Peripheral Arterial Disease · Northwestern University.
Among the 26 studies in Peripheral Arterial Disease by Northwestern University, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 23rd registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →8 of the 26 studies in Peripheral Arterial Disease by Northwestern University are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 50+
Northwestern University · Sites in United States
Ages 50+
Northwestern University · Sites in United States
Ages 50+
Northwestern University · Sites in United States
Ages 50+
By country, each count listing its studies:
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 7
First in 2007; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 192 across the 24 interventional studies, 557 across the 2 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
3 of the studies in Peripheral Arterial Disease by Northwestern University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04794530Phase 3Northwestern UniversityThe COCOA-PAD II Trial | 2026-12-31 |
| NCT06399809Northwestern UniversityFisetin to Reduce Senescence and Mobility Impairment in PAD | 2027-06-30 |
| NCT04228978Northwestern UniversityPromote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Peripheral Arterial Disease by Northwestern University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).
The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD) (Primary Aim #1). In Primary Aim #2, the investigators will measure the acute effect of the first treatment of 660 nm light on six-minute walk distance and on walking intensity (measured with the ActiGraph accelerometer) during the six-minute walk. In secondary and exploratory aims, the investigators will delineate biologic pathways by which 660 nm light enhances the benefits of home-based walking exercise, by measuring the effects of 660 nm light on exercise intensity during the exercise intervention and by measuring the effects of 660 nm light on plasma nitrosothiols, leg perfusion, and gastrocnemius muscle health and mitochondrial activity. Exercise intensity will be measured by the well validated ActiGraph accelerometer.
The ENLIGHTEN PAD Trial is a Phase II multi-centered randomized clinical trial. Thirty-two participants with PAD will be randomized at one of two centers: Northwestern University (PI: MM McDermott, MD) and the University of Alabama (PI: Nicole Lohr MD, PhD) to either 660 nm light + home-based exercise or sham light + home-based exercise for four months. Both groups of participants will receive the same home-based high intensity walking exercise intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subgroup of participants receiving home-based walking exercise and the 670 nm far red light device
Device: Far red light therapy · Behavioral: Home-based walking exercise
Subgroup of participants receiving home-based walking exercise and the sham light device, far red light device covered with blue filter paper to block 670 nm light, resulting in mean power generated of 0.24 mW/cm2, compared to 26.3 mW/cm2 for the intervention, a 100-fold difference.
Device: Sham light therapy · Behavioral: Home-based walking exercise
All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.
Six-Minute Walk Distance
Change in six-minute walk distance
Time frame: Measured at baseline and 4-month follow-up
Six-Minute Walk Distance
Change in six-minute walk distance (acute effect)
Time frame: Measured immediately after the first light treatment (within 15 minutes after the first treatment, acute effect)
Six-Minute Walk Distance
Change in six-minute walk distance (chronic effect)
Time frame: Measured at 4-month follow-up, 24 hours after the final treatment
Gastrocnemius Perfusion
Changes in calf perfusion at 3 Tesla measured with arterial spin labeling with MRI and post-cuff occlusion hyperemia
Time frame: Measured at baseline and 4-month follow-up
Minutes of High Intensity Exercise
Change in minutes of high intensity exercise/week (measured by the ActiGraph activity monitor)
Time frame: Measured at baseline and 4-month follow-up
Mean Exercise Intensity
Change in mean exercise intensity (measured by the ActiGraph activity monitor)
Time frame: Measured at baseline and 4-month follow-up
Mean Exercise Intensity During Six-Minute Walk
Change in mean exercise intensity during the six-minute walk (measured by the ActiGraph activity monitor)
Time frame: Measured at baseline and 4-month follow-up
Walking Impairment Questionnaire Distance Score
Participant report of difficulty walking increasingly longer distances. Score range 0-100, 100 is best
Time frame: Measured at baseline and 4-month follow-up
PROMIS Mobility Score
PROMIS mobility score from administered PROMIS questionnaire. Score range is from zero to infinity and a higher score means a better outcome.
Time frame: Measured at baseline and 4-month follow-up
Walking Impairment Questionnaire Speed Score
Participant report of ability to walking increasing number of stair flights (0-100 score, 100-best)
Time frame: Measured at baseline and 4-month follow-up
Walking Impairment Questionnaire Stair Climbing Score
Participant report of ability to walking increasing number of stair flights (0-100 score, 100-best)
Time frame: Measured at baseline and 4-month follow-up
Short-Form 36 (SF-36) Score (0-100 score, 100-best)
Change in score on the SF-36 from baseline to follow-up
Time frame: Measured at baseline and 4-month follow-up
Short Physical Performance Battery (SPPB)
SPPB range, range 0-12, 12-best
Time frame: Measured at baseline and 4-month follow-up
Plasma Nitrite
Changes in plasma abundance of nitrite
Time frame: Measured before and within five minutes after the first light treatment at baseline
Plasma Nitrite
Changes in plasma abundance of nitrite
Time frame: Measured before and within five minutes after the final light treatment at 4-month follow-up
Plasma Nitrosothiols
Changes in plasma abundance of nitrosothiols
Time frame: Measured before and within five minutes after the first light treatment at baseline
Plasma Nitrosothiols
Changes in plasma abundance of nitrosothiols
Time frame: Measured before and within five minutes after the final light treatment at 4-month follow-up
Gastrocnemius Muscle Capillary Density
Changes in gastrocnemius muscle capillary density
Time frame: Measured at baseline and 4-month follow-up
Gastrocnemius Muscle Myofiber Size
Changes in gastrocnemius muscle myofiber size
Time frame: Measured at baseline and 4-month follow-up
Gastrocnemius Muscle Citrate Synthase Activity
Changes in gastrocnemius muscle citrate synthase activity
Time frame: Measured at baseline and 4-month follow-up
Gastrocnemius Muscle Cytochrome C Oxidase Activity
Changes in gastrocnemius muscle cytochrome c oxidase activity
Time frame: Measured at baseline and 4-month follow-up
Gastrocnemius Muscle Abundance of Satellite Cells
Changes in gastrocnemius muscle abundance of satellite cells
Time frame: Measured at baseline and 4-month follow-up
Gastrocnemius Muscle Abundance of Myofibers with Central Nuclei
Changes in gastrocnemius muscle abundance of myofibers with central nuclei
Time frame: Measured at baseline and 4-month follow-up
Started Aug 2024 (actual). Primary completion is estimated for Sep 2026, 25 months after the start.
Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 25 months is below that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.